Product
Patsnap Eureka
For R&D, Patsnap Eureka makes reading and utilizing patents & technical documents easy.
Patsnap Eureka AIR
Designed for self-driven R&D workflows. Generate viable solutions, solve complex R&D challenges, empower your innovation with AI.
Patsnap Eureka Materials
Designed for material experts only. Revolutionize your material R&D, from search, analyze, to developing new materials.
Feature
TechResearch
Generate reliable direction feasibility study reports for your R&D in just a few steps.
TechSeek
Discover and master advanced knowledge NOW. Basics, ideas, possibilities, all at once.
TechMind
As an expert in R&D Theories, TechMind can generates customized viable solutions instantly.
TechRisk
Analyze your overall solution with one click, know your potential R&D risks in advance.
TechMonitor
Get weekly tech updates, stay abreast of the latest tech innovations and key insights.
Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
122 results about "Glaucoma treatments" patented technology
Efficacy Topic
Property
Owner
Technical Advancement
Application Domain
Technology Topic
Technology Field Word
Patent Country/Region
Patent Type
Patent Status
Application Year
Inventor
In the United States, treatment of open angle glaucoma usually begins with prescription eye drops. These medicines lower pressure inside the eye. As an alternative to medication or when medication fails to control glaucoma, laser surgery can be done. This surgery is called laser trabeculoplasty.
Implant with pressure sensor for glaucoma treatment
InactiveUS6981958B1Reduce morbidityAvoiding hypotonyEye surgeryInfusion needlesSchlemm's canalIntraocular pressure
Owner:GLAUKOS CORP
Combined treatment for cataract and glaucoma treatment
Owner:GLAUKOS CORP
Glaucoma treatment kit
A glaucoma treatment kit, containing intraocular stents and applicators, is disclosed. The stents are configured to extend between the anterior chamber and Schlemm's canal of the eye, for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure.
Owner:GLAUKOS CORP
Fluid infusion methods for glaucoma treatment
The invention relates to methods of treating glaucoma, such as a method that includes inserting a stent through an incision in an eye; the stent having an inflow portion that is in fluid communication with an outflow portion of the stent; transporting the stent from the incision through the anterior chamber of the eye to an aqueous cavity of the eye, such that the inflow portion of the stent is positioned in the anterior chamber and the outflow portion of the stent is positioned at the aqueous cavity; and infusing fluid from the inflow portion to the outflow portion of the stent.
Owner:GLAUKOS CORP
Medical device and methods of use of glaucoma treatment
InactiveUS7094225B2Lower eye pressureThe process is simple and effectiveBiocideSenses disorderAqueous outflowSchlemm's canal
The invention relates generally medical devices and methods for the treatment of glaucoma in an animal eye and, more particularly, to medical devices and methods for treating tissue of the trabecular meshwork and / or Schlemm's canal of the eye to restore or rejuvenate a portion or all of the normal physiological function of directing aqueous outflow for maintaining a normal intraocular pressure in the eye.
Owner:GLAUKOS CORP
Injectable gel implant for glaucoma treatment
InactiveUS20050277864A1Inhibit and slow effectEffective treatmentEye surgeryFlow mixersAqueous humorSchlemm's canal
Methods and implants for treating glaucoma in an eye are described. The implant includes an inlet section configured to be positioned in the anterior chamber of the eye and an outlet section in fluid communication with the inlet section. The outlet section is configured to be positioned in Schlemm's canal of the eye. The implant comprises a hydrogel and is configured to conduct aqueous humor from the anterior chamber to Schlemm's canal.
Owner:GLAUKOS CORP
Liquid jet for glaucoma treatment
Methods of treating glaucoma are described including treatment of an eye with a liquid jet. The liquid jet can be generated by a laser-induced liquid jet instrument which is inserted through an incision in an eye. A stent can also be used, the stent having an inflow portion that is in fluid communication with an outflow portion. The stent can be inserted into the eye and transported from the incision through the anterior chamber of the eye toward the trabecular meshwork of the eye. In some embodiments, the stent can be advanced through the anterior chamber of the eye and provide fluid communication between the anterior chamber and Schlemm's canal. The method includes infusing fluid into an aqueous cavity and increasing the pressure of the fluid within the aqueous cavity.
Owner:GLAUKOS CORP
Devices and methods for glaucoma treatment
ActiveUS20070276316A1Reduce morbidityAvoiding hypotonyStentsEye surgerySchlemm's canalIntraocular pressure
Intraocular stents and applicators are disclosed for treating glaucoma. The stents are configured to extend between the anterior chamber of the eye and Schlemm's canal for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure. The stents can have features for anchoring the stent into Schlemm's canal as well as preventing the walls of Schlemm's canal from closing the outlet of the stents. The applicators can be steerable so as to make implantation easier. Additionally, the applicators can be configured to hold a plurality of stents so that multiple stents can be implanted through one incision without removing the applicator from the incision between serial implantations.
Owner:GLAUKOS CORP
Fluid infusion methods for glaucoma treatment
InactiveUS20060116626A1Convenient treatmentReduce and inhibit and slow effectLaser surgeryEye implantsFluid infusionInsertion stent
Methods of treating glaucoma are disclosed, such as a method that includes inserting a stent through an incision in an eye; the stent having an inflow portion that is in fluid communication with an outflow portion of the stent; transporting the stent from the incision through the anterior chamber of the eye to an aqueous cavity of the eye, such that the inflow portion of the stent is positioned in the anterior chamber and the outflow portion of the stent is positioned at the aqueous cavity; and infusing fluid from the inflow portion to the outflow portion of the stent.
Owner:GLAUKOS CORP
Devices and methods for glaucoma treatment
InactiveUS20070276315A1Reduce morbidityAvoiding hypotonyStentsEar treatmentSchlemm's canalIntraocular pressure
Intraocular stents and applicators are disclosed for treating glaucoma. The stents are configured to extend between the anterior chamber of the eye and Schlemm's canal for enhancing outflow of aqueous from the anterior chamber so as to reduce intraocular pressure. The stents can have features for anchoring the stent into Schlemm's canal as well as preventing the walls of Schlemm's canal from closing the outlet of the stents. The applicators can be steerable so as to make implantation easier. Additionally, the applicators can be configured to hold a plurality of stents so that multiple stents can be implanted through one incision without removing the applicator from the incision between serial implantations.
Owner:GLAUKOS CORP
Combined treatment for cataract and glaucoma treatment
InactiveUS20070118147A1Maintain pressureFast and safe and less-expensiveEye surgerySurgeryGlaucoma proceduresSchlemm's canal
A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.
Owner:GLAUKOS CORP
Glaucoma stent and methods thereof for glaucoma treatment
InactiveUS20070112292A1Lower eye pressureReduce morbidityEye surgeryWound drainsAqueous outflowIntraocular pressure
The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.
Owner:GLAUKOS CORP
Implant with intraocular pressure sensor for glaucoma treatment
InactiveUS7678065B2Faster and safe and less-expensiveReduce morbidityEye implantsEye surgeryIntraocular pressureTreatment glaucoma
The invention discloses a trabecular stent and methods for treating glaucoma. The stent may incorporate an intraocular pressure sensor comprising a compressible element that is implanted inside an anterior chamber of an eye, wherein at least one external dimension of the element correlates with intraocular pressure. In some embodiments, the sensor may be coupled to the stent. Also disclosed are methods of delivery of the stent and the sensor to the eye.
Owner:GLAUKOS CORP
Combined treatment for cataract and glaucoma treatment
InactiveUS7951155B2Maintain pressureFast and safe and less-expensiveEye surgerySurgeryGlaucoma proceduresSchlemm's canal
A method is provided for treatment of cataract in combination with a glaucoma procedure while maintaining the intraocular pressure by permitting aqueous to flow out of an anterior chamber of the eye through a surgically stented pathway. A trabecular stent is adapted for implantation within the trabecular meshwork of an eye such that intraocular liquid flows controllably from the anterior chamber of the eye to Schlemm's canal, bypassing the trabecular meshwork. Depending upon the specific treatment contemplated, pharmaceuticals may be utilized in conjunction with the trabecular stent enabling post-cataract healing processes.
Owner:GLAUKOS CORP
Glaucoma Treatment Devices and Methods
InactiveUS20070156079A1Increased intraocular pressureReduce resistanceMaterial nanotechnologyEye surgerySurgeryTreatment glaucoma
This document provides methods and materials related to treating glaucoma. For example, devices that can be implanted into a human's eye to treat glaucoma, methods for treating glaucoma, compositions for reducing polypeptide clogging of implanted devices, and methods for making devices for treating glaucoma are provided.
Owner:BG IMPLANT
Glaucoma stent and methods thereof for glaucoma treatment
ActiveUS20140276332A1Lower eye pressureReduce morbidityEye surgeryIntravenous devicesAqueous outflowIntraocular pressure
The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.
Owner:GLAUKOS CORP
Aqueous humor drainage implant for treatment glaucoma
A first tube (3) and second tube (7) for guiding aqueous humor to the exterior of the eye are connected to each other in the vicinity of a surface of conjunctiva (14) via a first joint (5) and second joint (6). A filter part (9) provided to prevent reflux infection from the exterior to interior of the eye is connected to the second tube (7) via a third tube (8) positioned inside a lower lacrimal canaliculus (23). This enables an aqueous humor drainage implant (1) to be positioned in the eye and the exterior of the conjunctiva with reduced invasiveness. With the aqueous humor drainage implant for glaucoma treatment, the aqueous humor in the eye can be drained to the exterior of the conjunctiva while preventing reflux infection at the viral level, and the intraocular pressure reducing effect can be sustained for extended time periods over the lifespan of the patient. Further, the aqueous humor drainage implant can be readily positioned with reduced surgical invasiveness, while posing no danger of damaging the eye or nasolacrimal duct after the installation.
Owner:JAPAN SCI & TECH CORP
Glaucoma Treatment Device
InactiveUS20110306915A1Minimize scarringRemove complicationsEye implantsEar treatmentFlow diverterSuprachoroidal space
Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passageway between the suprachoroidal space and the anterior chamber.
Owner:NOVARTIS AG
Method of treating glaucoma
Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
Owner:ALCON RES LTD
Device and method for glaucoma management and treatment
ActiveUS20120302861A1Readily conform to eye contourMinimize traumaEye surgeryDiagnostic recording/measuringAqueous humourIOPS
Described herein is a device for glaucoma treatment and monitoring that comprises a combination of an intraocular pressure (IOP) sensor and a glaucoma drainage device. The device comprises an IOP sensor and an inductive antenna mounted within a porous biocompatible material that forms the drainage path. The IOP sensor is mounted in a footplate portion of the device and is mountable in the anterior chamber of an eye. The footplate portion is connected to a body portion that houses the spiral antenna by a neck portion which retains the footplate portion in a suitable position within the anterior chamber. Due to its size, the footplate portion housing the IOP sensor can readily be inserted into the anterior chamber with the body portion housing the spiral antenna located outside of the anterior chamber in a sub-scleral space to disperse the aqueous humour.
Owner:ISTAR MEDICAL
Remedy for glaucoma comprising rho kinase inhibitor and prostaglandins
InactiveUS20050245509A1Improve durabilityImprove actionBiocideSenses disorderGlaucomaProstaglandin a
A subject of the present invention is to find utility of a combination of a Rho kinase inhibitor and prostaglandins as a therapeutic agent for glaucoma. Actions of reducing intraocular pressure are complemented and / or enhanced each other by combining the Rho kinase inhibitor with prostaglandins. For the administration mode, each drug can be administered in combination or in mixture.
Owner:SANTEN PHARMA CO LTD
Method of treating glaucoma
Described are methods for the treatment of ocular hypertension or glaucoma comprising administering a pharmaceutically effective amount of one or more compounds that inhibit the enzyme EgLN-3. Certain embodiments of the invention combine the use of EgLN-3 with other glaucoma treatment agents. The compounds of the invention may be formulated in compositions comprising pharmaceutically acceptable carriers.
Owner:ALCON RES LTD
Glaucoma treatment method
Embodiments of the present invention provide a method and system of treating intraocular pressure. Laser light is directed to the ciliary region of the target eye. The light stimulates the ciliary region and ablates debris lodged therein. An immune response may be triggered by the stimulation of the ciliary body. Intraocular pressure is reduced by the increase in aqueous flow from the anterior chamber in the eye permitted by the resultant removal of debris blocking the uveo-scleral outflow pathway.
Owner:OCCULOGIX CORP
Glaucoma treatment device
Methods and devices are adapted for implanting into the eye. An incision is formed in the cornea of the eye and a shunt is inserted through the incision into the anterior chamber of the eye. The shunt includes a fluid passageway. The shunt is passed along a pathway from the anterior chamber through the scleral spur of the eye into the suprachoroidal space and positioned in a first position such that a first portion of the fluid passageway communicates with the anterior chamber and a second portion of the fluid passageway communicates with the suprachoroidal space to provide a fluid passagewaybetween the suprachoroidal space and the anterior chamber.
Owner:ALCON INC
Method for Laser Treatment for Glaucoma
ActiveUS20130289450A1Reduce convexityIncrease outflowUltrasound therapyLaser surgeryFiberDrainage angle
Because vision loss in most forms of glaucoma is related to elevated IOP, most glaucoma treatment protocols are concerned with lowering IOP by increasing aqueous humor outflow. The invention utilizes electromagnetic radiation to create retraction in the iris tissue, thereby (a) reducing convexity and enlarging the drainage angle and thus the area of the anterior chamber, (b) reducing contact between the zonule fibers and the iris pigment epithelium, (c) applying greater tension to both the TM and uveoscleral outflow pathways, thereby enlarging those pathways and increasing outflow.
Owner:HOMER GREGG S
Cytoskeletal active agents for glaucoma therapy
InactiveUS20020045585A1Lower eye pressureImprove fluid flowBiocideSenses disorderActin cytoskeletonActive agent
Methods for the treatment of glaucoma are provided by the present invention. The compounds described cause a perturbation of the actin cytoskeleton in the trabecular meshwork or the modulation of its interactions with the underlying membrane. Perturbation of the cytoskeleton and the associated adhesions reduces the resistance of the trabecular meshwork to fluid flow and thereby reduces intraocular pressure.
Owner:YEDA RES & DEV CO LTD +1
Medical device and methods of use for glaucoma treatment
InactiveUS20060047263A1Lower eye pressureThe process is simple and effectiveGogglesMedical devicesAqueous outflowSchlemm's canal
The invention relates generally medical devices and methods for the treatment of glaucoma in an animal eye and, more particularly, to medical devices and methods for treating tissue of the trabecular meshwork and / or Schlemm's canal of the eye to restore or rejuvenate a portion or all of the normal physiological function of directing aqueous outflow for maintaining a normal intraocular pressure in the eye.
Owner:GLAUKOS CORP
Glaucoma treatment methods and apparatus
InactiveUS20180207029A1Increase outflowHigh porosityLaser surgeryUltrasound therapySchlemm's canalUvea
The methods and apparatus disclosed herein can be used to treat glaucoma of the eye. The methods and apparatus can be configured to apply energy to the sclera, cornea, and / or other regions of the eye in order to shrink collagenous tissue near Schlemm's canal. Juxtacanalicular treatment of the sclera and / or cornea adjacent Schlemm's canal can be used to dilate Schlemm's canal, collector channels, and / or the Trabecular Meshwork. The methods and apparatus can be configured to apply energy to the sclera to generate scleral vacuoles in the sclera to improve uveoscleral outflow.
Owner:ALEYEGN TECH LLC
Trans-corneal shunt and method
A method for relieving pressure within the eye in the treatment of glaucoma comprising inserting an extremely thin flat trans-corneal drainage shunt, having no detrimental cap or footplate, within a self-sealing incision made by a keratome knife within the cornea at the limbus, the drainage shunt having extremely small pores formed therein for the controlled transport of aqueous fluid from an anterior portion of the eye to the tear film on the surface of the eye while deterring bacteria from entering the eye, and fixing the position of the trans-corneal shunt in position within the cornea by means of a suture. The shunt can be tapered for preventing an unacceptable degree of intrusion of the shunt into the anterior portion of the eye. The trailing edge portion of the shunt is wide relative to other portions of the shunt, thereby facilitating grasping of the shunt when desired.
Owner:WANDEL THADDEUS
Glaucoma stent and methods thereof for glaucoma treatment
The invention relates generally to medical devices and methods for reducing the intraocular pressure in an animal eye and, more particularly, to stent type devices for permitting aqueous outflow from the eye's anterior chamber and associated methods thereof for the treatment of glaucoma. Some aspects provide a self-trephining glaucoma stent and methods thereof which advantageously allow for a “one-step” procedure in which the incision and placement of the stent are accomplished by a single device and operation. This desirably allows for a faster, safer, and less expensive surgical procedure.
Owner:GLAUKOS CORP
Who we serve
- R&D Engineer
- R&D Manager
- IP Professional
Why Patsnap Eureka
- Industry Leading Data Capabilities
- Powerful AI technology
- Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.
© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com